Leisha A. Emens, MD, PhD

home / authors / leisha-a-emens-md-phd

Articles

Dr. Emens on Immune-Related Adverse Events in Ovarian Cancer

Dr. Emens on Immune-Related Adverse Events in Ovarian Cancer

Leisha A. Emens, MD, PhD
March 4th 2020

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

Read More

Dr. Emens on Combining Checkpoint Inhibitors With PARP Inhibitors in Ovarian Cancer

Dr. Emens on Combining Checkpoint Inhibitors With PARP Inhibitors in Ovarian Cancer

Leisha A. Emens, MD, PhD
February 21st 2020

Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.

Read More

Dr. Emens on the Future of Immunotherapy in Ovarian Cancer

Dr. Emens on the Future of Immunotherapy in Ovarian Cancer

Leisha A. Emens, MD, PhD
December 23rd 2019

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Read More

Latest Updated Articles

Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: March 26th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
RLY-2608
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
Published: February 11th 2025 | Updated: February 14th 2025
Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial